Business Wire

TX-PURIFY-FUEL

5.2.2020 00:05:11 CET | Business Wire | Press release

Share
Purify Fuel’s nanO2 Combustion Catalyst® to Be Distributed in the Middle East by Kanoo Blue

Purify Fuel, Inc. (PFI), creator of the nanO2 Combustion Catalyst® that helps diesel consumers save money and reduce emissions, announced today that it has signed an exclusive distribution deal with Kanoo Blue. Purify Fuel’s nanO2 Combustion Catalyst optimizes performance and fuel efficiency in Marine Gasoil (MGO), making MGO a more cost-effective solution than Very Low Sulphur Fuel Oil (VLSFO).

Blending nanO2 Combustion Catalyst with MGO allows shipowners to avoid the compatibility issues associated with VLSFO blends and the mechanical challenges associated with running on multiple fuel types while increasing efficiency and saving money.

Further, with the recent implementation of IMO 2020’s sweeping legislation effective January 1, 2020, VLSFO prices have increased above MGO. While this trend may not hold, VLSFO pricing at/or near MGO reinforces the case for using Purify Fuel’s nanO2 Combustion Catalyst.

Through the agreement, Kanoo will act as the exclusive distribution partner in the region, helping customers in the marine, mining, oil services, transportation and power generation markets to achieve cleaner and more efficient diesel. Kanoo Blue focuses on identifying and bringing to its clients the best breakthrough technologies currently available in the world of science and technology across a wide spectrum of business segments.

“This partnership is not just good economically for the region, but it’s also great for environmental sustainability,” says Bader Abdulaziz Kanoo, Kanoo Blue Chairman. “Purify Fuel’s nanO2 Combustion Catalyst solution will help diesel engines work more efficiently while simultaneously helping to reduce harmful emissions. The timing for Purify Fuel could not be better as the region and the world search for cleaner fossil fuel options.”

“This deal builds on our first exclusive distribution partnership with Mencast Holdings, making Purify Fuel’s nanO2 Combustion Catalyst available in three of the world’s largest refueling ports — Singapore, Fujairah, and Shanghai — with annual sales of more than 20 billion gallons,” says John Carroll, CEO of Purify Fuel. “Additionally, through the efforts of our marine lead, John ‘Fozzie’ Miller, VADM (Ret), United States Navy, we are well on our way to meeting our goal of being distributed in 60% of the world’s largest ports.”

This exciting partnership will be on display at the Middle East Bunkering Convention , in Dubai. If you are a shipowner in the region and would like to learn more about how to leverage nanO2 to save money and reduce emissions, please contact us by visiting www.purifyfuel.com to schedule a meeting.

About Kanoo Blue:

Kanoo Blue was established in Bahrain for the purpose of bringing disruptive technologies to the Middle East and Africa, in the field of Energy, Nano Technology, Industrial IT, Artificial Intelligence, Bio-Technology, Water and other much needed high-end technologies to the region. Kanoo Blue is also the commercial partner for Houston Technologies, Middle-East for its portfolio of leading-edge disruptive technologies.

About Purify Fuel:

Purify Fuel creates patented nanotechnology-based rare earth oxides to help large diesel operators save money and reduce emissions. Purify Fuel’s nanO2 Combustion Catalysts® are custom blended to optimize diesel fuel and biodiesel blends for marine, fracking, military, mining, power generation, and rail markets. The combustion catalysts increase energy harvested from each gram of fuel while reducing particulate matter emissions and soot created by incomplete combustion. Purify Fuel works directly with large consumers of diesel and biodiesel fuel to help them save money, increase power, and reduce emissions.

For more information on Purify Fuel, please visit www.purifyfuel.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye